Browse Category

NASDAQ:NBIS News 28 December 2025 - 6 February 2026

Nebius stock snaps higher in premarket after two-day slide as NBIS earnings near

Nebius stock snaps higher in premarket after two-day slide as NBIS earnings near

Nebius Group N.V. shares rose 4.8% to $77.41 in premarket trading Friday, rebounding after an 18% two-day drop amid a broader tech selloff. The Amsterdam-based AI cloud firm will report fourth-quarter and full-year 2025 results on Feb. 12. Investors are focused on Nebius’s spending plans and revenue outlook as scrutiny of capital expenditures in the sector intensifies.
Nebius (NBIS) stock price drops 7% as Microsoft-led tech rout hits AI cloud names

Nebius (NBIS) stock price drops 7% as Microsoft-led tech rout hits AI cloud names

Nebius shares fell 7.4% to $93.01 Thursday, reversing an early rally as investors weighed Microsoft’s rising AI costs and Meta’s larger capex plans, which include Nebius as a cloud partner. The stock traded between $91.24 and $100.80. Selling spread to other AI-linked stocks, with CoreWeave down 8.6%. Markets await Apple’s earnings for further signals on tech and AI investment.
Nebius (NBIS) stock swings as Israel AI supercomputer launch hits tape, investors eye contract deadlines

Nebius (NBIS) stock swings as Israel AI supercomputer launch hits tape, investors eye contract deadlines

Nebius Group shares fell 0.1% to $98.73 Thursday after swinging more than 5% earlier, with about 8 million shares traded. The company is supplying GPU infrastructure for Israel’s new national AI supercomputer and holds a $17.4 billion contract with Microsoft, but faces risks from a conditional $2.9 billion Meta deal and rising losses tied to rapid expansion. Next earnings are expected in February.
Nebius (NBIS) stock price slips after-hours as Israel AI supercomputer news meets jittery tape

Nebius (NBIS) stock price slips after-hours as Israel AI supercomputer news meets jittery tape

Nebius shares fell 0.4% to $98.87 in after-hours trading Wednesday after a volatile session. The drop keeps the stock below $100 following an 8.7% plunge Tuesday. Israel launched a national AI supercomputer using Nebius infrastructure and Nvidia B200 chips. Investors remain alert to tariff developments and the company’s next earnings date.
Nebius (NBIS) stock slides 7% as Israel opens AI supercomputer access — what investors watch next

Nebius (NBIS) stock slides 7% as Israel opens AI supercomputer access — what investors watch next

Nebius Group shares fell 7.4% to $100.65 in early Tuesday trading, underperforming the broader tech sector. The drop followed news that Israel’s Innovation Authority launched its AI supercomputer, built by Nebius, with access now live for companies and researchers. Nebius reported $146.1 million in quarterly revenue but posted losses over $100 million as capital spending surged.
Nebius (NBIS) stock jumps on report of 800MW Kansas City-area data center plan

Nebius (NBIS) stock jumps on report of 800MW Kansas City-area data center plan

Nebius shares jumped 10.2% to $107.87 Monday after reports of an 800-megawatt AI data center campus planned near Kansas City. The $6.6 billion project, proposed for Independence, Missouri, would span up to 10 buildings and 400 acres, with construction expected to start in early 2026. Investors are watching local approvals and the pace of power infrastructure development.
Nebius (NBIS) stock ticks up as AI names rebound — Rubin rollout and earnings are the next tests

Nebius (NBIS) stock ticks up as AI names rebound — Rubin rollout and earnings are the next tests

Nebius shares rose 1.2% to $98.48 Friday afternoon after swinging above $104 earlier in the session. The move followed gains in chip stocks and AI infrastructure names, with Nvidia up 0.5% and Applied Digital jumping over 17%. Traders are watching Nebius’ plans to offer Nvidia’s Rubin GPUs in late 2026 and its next earnings report, expected Feb. 18.
Nebius (NBIS) stock bounces back near $100 as Nvidia Rubin talk keeps AI cloud names jumpy

Nebius (NBIS) stock bounces back near $100 as Nvidia Rubin talk keeps AI cloud names jumpy

Nebius shares rose nearly 4% to $100.03 in midday Nasdaq trading Thursday after the AI cloud company announced plans to offer early access to Nvidia’s Rubin platform starting in the second half of 2026. The stock rebounded after a previous session drop, while Nvidia slipped 2%. Investors are watching a Jan. 29 product webinar and the company’s next earnings update in mid-February.
Nebius stock jumps about 7% as chips rally in first U.S. session of 2026 (NBIS)

Nebius stock jumps about 7% as chips rally in first U.S. session of 2026 (NBIS)

NEW YORK, Jan 2, 2026, 15:09 ET — Regular session Shares of Nebius Group N.V. were up 7.4% at $89.91 on Friday afternoon, extending a rebound in AI infrastructure-linked stocks as chip names led the market. The move matters because Nebius is widely seen as a high-beta proxy for demand for graphics processing units, or GPUs — chips used to train and run artificial intelligence models. When investors lean into AI hardware, smaller infrastructure suppliers often swing harder. Friday was the first full U.S. trading session of 2026, with traders recalibrating risk after last year’s gains and turning to early-year
Nebius (NBIS) stock dips in premarket as Wall Street kicks off 2026 — what to watch next

Nebius (NBIS) stock dips in premarket as Wall Street kicks off 2026 — what to watch next

NEW YORK, January 2, 2026, 04:52 ET — Premarket Nebius Group N.V. shares were down about 1.7% at $83.71 in premarket trading on Friday, compared with a prior close near $85.15. The early move comes as traders return from the New Year holiday with a fresh set of macro cross-currents, and with the market’s “AI trade” still a key driver of risk-taking. Reuters That matters for Nebius because the company is tied to the AI infrastructure buildout — capital-intensive work that tends to trade on confidence in demand, financing conditions and delivery execution. SEC+1 Broader sentiment looked supportive early Friday,
2 January 2026
Nebius stock dips into New Year holiday as insider sale notice puts Jan. 2 in focus

Nebius stock dips into New Year holiday as insider sale notice puts Jan. 2 in focus

NEW YORK, January 1, 2026, 16:35 ET — Market closed Nebius Group N.V. (NBIS) shares slipped into the year-end close, last down about 1.7% at $83.71, as traders headed into a holiday shutdown and weighed a newly disclosed planned insider sale. SEC The move matters because there is no fresh price discovery today, with U.S. exchanges shut for New Year’s Day. The next read on risk appetite for high-beta AI infrastructure names comes when trading resumes on Friday, Jan. 2. Nasdaq Nebius is a Netherlands-based infrastructure company focused on cloud and tooling for AI workloads, according to Reuters’ company description.
Nebius Group (NBIS) stock falls as insider sale filings surface ahead of Jan. 2 trading restart

Nebius Group (NBIS) stock falls as insider sale filings surface ahead of Jan. 2 trading restart

NEW YORK, December 31, 2025, 20:44 ET — Market closed Nebius Group N.V. shares ended down 1.7% at $83.71 on Wednesday, after U.S. filings showed several insiders planned sales of the company’s Class A ordinary shares in early January. The stock traded between $82.94 and $86.41, with about 7.1 million shares changing hands. The disclosure matters because Nebius has been a high-beta proxy for the AI infrastructure buildout, where sentiment can swing quickly on any sign of incremental supply. Investors in the group have also been focused on dilution risk and funding needs as the company ramps capacity. Timing adds
1 January 2026
Nebius (NBIS) stock slips after insider sale notices hit SEC filings in thin year-end trade

Nebius (NBIS) stock slips after insider sale notices hit SEC filings in thin year-end trade

NEW YORK, December 29, 2025, 19:45 ET — After-hours Nebius Group N.V. shares slid on Monday after SEC filings showed founder Arkady Volozh and two other insiders planned share sales around year-end. The stock was down 1.8% at $86.04 in late trade. SEC+2SEC+2 The notices matter now because NBIS has been a high-beta trade — a stock that tends to swing more than the market — and additional supply can weigh on prices when liquidity is thin in the final days of the year. The filings landed as U.S. stocks dipped broadly, with the Nasdaq ending down 0.5%. “We’re seeing
30 December 2025
Nebius Group (NBIS) Stock: Weekend Recap, Fresh Headlines, Analyst Targets, and What to Watch Before Monday’s Open

Nebius Group (NBIS) Stock: Weekend Recap, Fresh Headlines, Analyst Targets, and What to Watch Before Monday’s Open

NEW YORK, Dec. 28, 2025, 2:48 p.m. ET — Market closed Nebius Group N.V. (Nasdaq: NBIS) heads into the final trading days of 2025 with investors still debating a familiar AI-infrastructure question: is the recent pullback a healthy reset—or the start of a deeper volatility cycle? Friday’s session offered a reminder of how quickly sentiment can swing in high-beta “AI buildout” names, even as the company continues to stack headline-sized contracts and capacity plans. NBIS ended Friday at $87.59, down about 3.9% on the day, after trading as low as $86.74. Trading volume was also lighter than usual versus the
28 December 2025
1 2 3

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop